Xtant Medical Announced the Launch of SimipliGraft TM and SimpliMaxTM for Chronic and Acute Wounds
On April 30, 2024, Xtant Medical Holdings, Inc., a global medical technology firm specializing in surgical remedies for spinal disorders, announced the complete commercial availability of two amniotic membrane allografts, known as SimpliGraft™ and SimpliMax™.
SimpliGraft and SimpliMax are dehydrated, terminally irradiated sheets of amniotic membrane, available in single and dual layers. They are designed to act as a barrier, offering protective coverage against the surrounding environment when applied topically to both chronic and acute wounds. These products...